SPERO EUROPE LIMITED

Active London

Research and experimental development on biotechnology

0 employees website.com
Research and experimental development on biotechnology
S

SPERO EUROPE LIMITED

Research and experimental development on biotechnology

Founded 18 Aug 2015 Active London, United Kingdom 0 employees website.com
Research and experimental development on biotechnology
Accounts Submitted 29 Oct 2025 Next due 30 Sept 2026 4 months remaining
Confirmation Submitted 12 Aug 2025 Next due 17 Aug 2026 3 months remaining
Net assets £-2M £43K 2024 year on year
Total assets £0
Total Liabilities £2M £43K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

6th Floor One London Wall London EC2Y 5EB United Kingdom

Full company profile for SPERO EUROPE LIMITED (09738422), an active company based in London, United Kingdom. Incorporated 18 Aug 2015. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2023–2024)

Cash in Bank

N/A

Net Assets

-£1.90M

Decreased by £42.79k (-2%)

Total Liabilities

£1.90M

Increased by £42.79k (+2%)

Turnover

N/A

Employees

N/A

Debt Ratio

N/A

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

2 active 1 resigned
Status
Ankit Atul MahadeviaDirectorAmericanUnited States4618 Aug 2015Active
Patrick Volkert Jozef Johannes VinkDirectorDutchSwitzerland6215 Oct 2015Active

Shareholders

Shareholders (1)

Spero Therapeutics, Inc.
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active

Spero Therapeutics, Inc

United States Of America

Active
Notified 17 Jun 2017
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

SPERO EUROPE LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
29 Oct 2025AccountsAnnual accounts made up to 31 Dec 2024
12 Aug 2025Confirmation StatementConfirmation statement made on 3 Aug 2025 with no updates
30 Sept 2024AccountsAnnual accounts made up to 31 Dec 2023
13 Aug 2024Confirmation StatementConfirmation statement made on 3 Aug 2024 with no updates
5 Sept 2023Confirmation StatementConfirmation statement made on 3 Aug 2023 with no updates
29 Oct 2025 Accounts

Annual accounts made up to 31 Dec 2024

12 Aug 2025 Confirmation Statement

Confirmation statement made on 3 Aug 2025 with no updates

30 Sept 2024 Accounts

Annual accounts made up to 31 Dec 2023

13 Aug 2024 Confirmation Statement

Confirmation statement made on 3 Aug 2024 with no updates

5 Sept 2023 Confirmation Statement

Confirmation statement made on 3 Aug 2023 with no updates

Recent Activity

Latest Activity

Annual accounts made up to 31 Dec 2024

6 months ago on 29 Oct 2025

Confirmation statement made on 3 Aug 2025 with no updates

8 months ago on 12 Aug 2025

Annual accounts made up to 31 Dec 2023

1 years ago on 30 Sept 2024

Confirmation statement made on 3 Aug 2024 with no updates

1 years ago on 13 Aug 2024

Confirmation statement made on 3 Aug 2023 with no updates

2 years ago on 5 Sept 2023